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Carvacrol, a phenolic monoterpene, has been reported to possess anti-inﬂammatory properties.
However, the mechanisms involved in its pharmacological properties are currently not well under-
stood. In the present study, the contribution of cytokine modulation to the anti-inﬂammatory effects of
carvacrol was investigated in a classical inﬂammation model: the complete Freund’s adjuvant (CFA)-
induced paw inﬂammation in mice. The paw edema was measured using a plesthismometer. Paw tissue
was removed 2 h after the inﬂammatory stimulus to determine the levels of prostaglandin E2 (PGE2) by
enzyme immunoassay, the levels of interleukin-1 b (IL-1b), tumor necrosis factor-a (TNF-a), and
interleukin-10 (IL-10) by ELISA or the mRNA expression of cyclooxygenase-2 (COX-2), IL-1b, TNF-a, and
IL-10 by real-time PCR. Administration of carvacrol produced anti-inﬂammatory effects against CFA-
induced inﬂammation in mice. Treatment of mice with carvacrol at 50 and 100 mg/kg attenuated the
paw edema and reduced the IL-1b and PGE2, but not TNF-a, local levels. Similarly, carvacrol (100 mg/kg)
reduced the COX-2 and IL-1b mRNA expression. The levels of IL-10, an anti-inﬂammatory cytokine, and
the IL-10 mRNA expression in the inﬂamed paw were enhanced by carvacrol. In addition, the treatment
with carvacrol did not reduce the CFA-induced paw edema in IL-10 knockout mice. The present results
suggest that carvacrol causes anti-inﬂammatory effects by reducing the production of inﬂammatory
mediators, such as IL-1b and prostanoids, possibly through the induction of IL-10 release.
& 2012 Elsevier B.V. Open access under the Elsevier OA license. 1. Introduction
It is well accepted that cytokines constitute a link between
cellular injuries and signs of inﬂammation, e.g., in cell migration,
edema, fever, and hyperalgesia (Conti et al., 2004; Cunha and
Ferreira, 2003; Hopkins, 2003). Cytokines are produced and released
from various cell types in response to inﬂammatory stimuli. The
release of inﬂammatory cytokines, such as interleukin-1 b (IL-1b)
and tumor necrosis factor-a (TNF-a), is followed by that of
anti-inﬂammatory cytokines, such as interleukin-10 (IL-10) and
interleukin-4 (IL-4) (Hopkins, 2003). Inﬂammatory cytokines induce
the production of mediators involved in the induction of inﬂamma-
tory signs, while anti-inﬂammatory cytokines inhibit the productiona Tecidual e Imunofarmacolo-
swaldo Cruz, Rua Waldemar
ier OA license. of inﬂammatory cytokines (Verri et al., 2006). In line with this idea,
the balance between pro- and anti-inﬂammatory cytokine produc-
tion modulates the intensity of inﬂammation.
It has been demonstrated that natural products are a potential
source of cytokine production inhibitors (Lima et al., 2011;
Nonato et al., 2011; Oliveira et al., 2011). In contrast with non-
steroidal anti-inﬂammatory drugs, widely used medications to
treat inﬂammatory conditions, inhibitors of cytokine production
can exhibit disease-modifying activities, thus representing an
alternative therapeutic strategy for the control of inﬂammatory
diseases. Carvacrol (5-isopropyl-2-methylphenol) is a phenolic
monoterpene presented in the essential oil of the family Lamia-
ceae, which includes the genera Origanum and Thymus (Baser,
2008). Previous studies have demonstrated that carvacrol has
anti-inﬂammatory properties (Botelho et al., 2009; Guimar~aes
et al., 2012; Hotta et al., 2010; Landa et al., 2009; Wagner et al.,
1986); however, the mechanisms involved in its pharmacological
activities are currently not well understood. Considering the key
role of cytokines during inﬂammation, the present study was
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to the anti-inﬂammatory effects of carvacrol.2. Materials and methods
2.1. Animals
Experiments were performed using male Swiss mice (22–28 g)
raised and maintained in the animal facilities at Gonc-alo Moniz
Research Center, FIOCRUZ/BA. IL-10 knockout experiments were
performed using male C57BL/6 wild-type (WT) and IL-10-
deﬁcient (IL-10 KO) mice. Animals were housed in temperature-
controlled rooms (22–25 1C), under a 12:12 h light-dark cycle,
with access to water and food ad libitum until use. All behavioral
tests were performed between 8:00 a.m. and 5:00 p.m., and
animals were only used once. Animal care and handling proce-
dures were in accordance with the Institutional Animal Care and
Use Committee of the Gonc-alo Moniz Research Center (FIOCRUZ
L-029/2009). All efforts were made to minimize the number of
animals used and their discomfort.
2.2. Inﬂammatory pain model
Mice were slightly anesthetized with halothane and received
10 ml of complete Freund’s adjuvant (CFA; 1 mg/ml of heat-killed
Mycobacterium tuberculosis in 85% parafﬁn oil and 15% mannide
monoleate; Sigma, St. Louis, MO, USA) subcutaneously in the plantar
region of the right hind paw, according to a method reported
previously (Kassuya et al., 2003). Paw edema and cytokines produc-
tion were measured as described below.
2.3. Paw edema measure
The volume of the mouse paws was measured with a plesthism-
ometer (Ugo Basile, Comerio, Italy) before (Vo) and after (VT) the
intraplantar injection of CFA, as described previously (Winter et al.,
1962). The amount of paw swelling was determined for each mouse
and the difference between VT and Vo was taken as the edema value
(mm3/paw).
2.4. Cytokine measurement by ELISA
Skin tissues were removed from the paws 2, 4, and 24 h after
the intraplantar injection of CFA (10 ml/paw), in mice terminally
anesthetized from each experimental group. Tissue proteins were
extracted from 100 mg tissue/ml PBS to which 0.4 M NaCl, 0.05%
Tween 20, and protease inhibitors (0.1 mM PMSF, 0.1 mM ben-
zethonium chloride, 10 mM EDTA, and 20 KIU aprotinin A/100 ml)
were added. The samples were centrifuged for 10 min at 3000g and
the supernatant was frozen at 70 1C for later quantiﬁcation
(Santiago et al., 2006). IL-1b, TNF-a and IL-10 levels were esti-
mated using commercially available immunoassay ELISA kits for
mice (R&D System, Minneapolis, MN, USA), according to the
manufacturer’s instructions. The results are expressed as pico-
grams of cytokine per milliliter of protein solution. As controls, the
concentrations of these cytokines in saline and vehicle-treated
mice were determined.
2.5. Determination of PGE2 levels
The methodology used was similar to that previously described
(Pinheiro and Calixto, 2002). Two hours after the intraplantar
injection of CFA (10 ml/paw), mice were sacriﬁced using deep CO2
anesthesia, and paw skin tissue samples were collected and soaked
in 2 ml of PBS containing heparin (5 IU/ml). Indomethacin (50 mg/ml)was added to prevent further production of PGE2. After homogeniza-
tion, samples were centrifuged at 1300g for 10 min at 4 1C, and the
supernatants collected and rapidly frozen and stored at 70 1C until
analysis. Levels of PGE2 were determined using commercially avail-
able enzyme immunoassay (EIA) kit according to the manufacturer’s
recommendations (Cayman Chemical, Ann Arbor, MI, USA).
2.6. Real-time PCR
The transcription of cyclooxygenase-2 (COX-2), IL-1b, TNF-a
and IL-10 genes was evaluated by real-time quantitative poly-
merase chain reaction (qRT-PCR) in mice sacriﬁced 2 h after the
CFA injection. Total RNA was isolated from the paw tissue with
TRIzol reagent (Invitrogen Corporation, Carlsbad, CA, USA), and
the concentration was determined by photometric measurement.
A High Capacity cDNA Reverse Transcription Kit (Applied Biosys-
tems, Foster City, CA, USA) was used to synthesize cDNA from
1 mg of RNA following the manufacturer’s recommendations. The
qRT-PCR assays were performed to detect the expression levels of
COX-2, TNF-a, IL-1b, and IL-10 genes. Ampliﬁcation mixtures for
qRT-PCR contained 20 ng template cDNA, 10 ml Taqman Master
Mix (Applied Biosystems) and probes in a ﬁnal volume of 20 ml.
All reactions were run in duplicate on an ABI7500 Sequence
Detection System (Applied Biosystems) under standard thermal
cycling conditions. Experiments with coefﬁcients of variation
greater than 5% were excluded. A no-template control (NTC)
and no-reverse transcription controls (No–RT) were also included.
The results are presented as the fold-increase of expression of the
individual mRNAs, with the target internal control GADPH using
the cycle threshold method.
2.7. Test compounds and stimuli
Complete Freund’s adjuvant, carvacrol (98% purity), and dexa-
methasone were purchased from Sigma (St. Louis, MO, USA). Drugs
were administrated by intraperitoneal (i.p.) route. Carvacrol was
dissolved in 5% Tween 20 plus saline, and dexamethasone was
dissolved in ethanol (10% in saline solution).
2.8. Statistical analyses
Data are presented as means7standard error of the mean
(S.E.M.) of measurements made on 6 animals in each group.
Comparisons between three or more treatments were made using
one-way ANOVA with Tukey’s post-hoc test or, repeated mea-
sures of two-way ANOVA with Bonferroni’s post-hoc test, as
appropriate. All data were analyzed using Prism 5 Computer
Software (GraphPad, San Diego, CA, USA). Statistical differences
were considered to be signiﬁcant at Po0.05.3. Results
Administration of carvacrol (50 and 100 mg/kg, i.p.), 40 min
before CFA, reduced signiﬁcantly (Po0.01) the CFA-induced paw
edema up to 24 h after the stimuli (Fig. 1). The results obtained
with control groups supported the effects observed with carvacrol
administration, since vehicle (5% Tween 20 in saline) had no
activity, whereas dexamethasone (2 mg/kg), the reference drug,
inhibited the CFA-induced edema (Po0.01).
The modulatory action of carvacrol on cytokine production
was next evaluated. As shown by qRTPCR analysis, pretreatment
with carvacrol (100 mg/kg, i.p.) reduced the local expression of
IL-1b mRNA (Po0.05), but not TNF-a mRNA, during CFA-induced
paw inﬂammation (Fig. 2B and C, respectively). Conﬁrming these
results, the paw levels of IL-1b, but not of TNF-a, were reduced
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The kinetics of IL-1b production showed that the inhibitory
effects of carvacrol persisted until 24 h after CFA challenge
(Fig. 3D). As expected, the pretreatment with dexamethasone
(2 mg/kg, i.p.) reduced the production of TNF-a and IL-1b induced
by CFA (Fig. 3; Po0.05).
Aiming to evaluate a possible inhibition of prostanoid production
by carvacrol, the levels of PGE2 and the expression of COX-2 mRNA
were evaluated. Mice pretreated with carvacrol (50 and 100 mg/kg)
or dexamethasone (0.5 mg/kg) had a signiﬁcant (Po0.01) decreaseFig. 1. Effects of carvacrol on complete Freund’s adjuvant (CFA)-induced paw
inﬂammation. Paw edema measured at 2, 4, 24, and 48 h after the CFA injection.
Mice were injected with carvacrol (CA; 25, 50 and 100 mg/kg), vehicle (5% Tween
20 in saline; control group) or dexamethasone (Dexa; 2 mg/kg; reference drug) by
the intraperitoneal route 40 min before CFA (injected at time zero). The saline
group received intraplantar injection of saline solution (10 ml/paw) instead of CFA.
Data are expressed as means7S.E.M.; n¼6 mice per group. n Signiﬁcantly
different from the control group (Po0.01); #signiﬁcantly different from the saline
group (Po0.001). Two-way ANOVA followed by Bonferroni’s test.
Fig. 2. Effects of carvacrol on COX-2 mRNA (A), IL-1b mRNA (B), TNF-a mRNA (C), and
vehicle (5% Tween 20 in saline; control group) by the intraperitoneal route 40 min befor
COX-2 mRNA, IL-1bmRNA, TNF-amRNA, and IL-10 mRNA were measured by qRTPCR 2
(10 ml/paw) instead of CFA. Data are reported as means7S.E.M.; n¼6 mice per g
#signiﬁcantly different when compared to the saline group (Po0.01). One-way ANOVAin PGE2 levels in the paw after CFA injection (Fig. 4). Similarly, a
reduction of COX-2 mRNA expression was observed in the paws of
carvacrol-treated mice (Fig. 2A; Po0.05).
Next we evaluated the contribution of IL-10, an anti-
inﬂammatory cytokine, to the carvacrol-induced anti-inﬂamma-
tory effect. Pretreatment with carvacrol (100 mg/kg) induced a
signiﬁcant increase (Po0.01) of the paw expression of IL-10
mRNA (Fig. 2D). Similarly, the local production of IL-10 (Fig. 3E)
was enhanced by carvacrol at 50 mg/kg (Po0.01) and 100 mg/kg
(Po0.001). The effects of carvacrol on IL-10 production lasted for
24 h (Fig. 3F). Moreover, pretreatment with carvacrol, at a similar
range of doses, did not reduce the CFA-induced paw edema in
IL-10 knockout mice (Fig. 5).4. Discussion
In the present study, aiming to understand the mechanisms by
which carvacrol induces its anti-inﬂammatory effects, the pro-
duction of important mediators of inﬂammation was evaluated.
Treatment of mice with carvacrol, at a similar range of doses,
attenuated the paw edema and inhibited key events related to
inﬂammation, namely, the local increase of IL-1b and PGE2 levels
and the induction of COX-2 expression. In addition, carvacrol
enhanced the local IL-10 release, while was unable to reduce the
inﬂammation in IL-10 knockout mice. Therefore, the present data
suggest that carvacrol induces anti-inﬂammatory effects by redu-
cing the production of IL-1b and PGE2, important inﬂammatory
mediators, possible through a mechanism dependent on IL-10
production.
Using an experimental protocol for screening of new anti-
inﬂammatory drugs, the CFA-induced paw inﬂammation model, the
mechanisms involved with the anti-inﬂammatory action of carvacrol
were investigated. Administration of carvacrol reduced the CFA-
induced paw edema, conﬁrming the data from Guimar~aes et al.
(2012) showing that carvacrol has anti-edematogenic properties inIL-10 mRNA (D) paw levels. Mice were injected with carvacrol (CA; 100 mg/kg) or
e the intraplantar injection of complete Freund’s adjuvant (CFA). The paw levels of
h after the CFA injection. The saline group received intraplantar injection of saline
roup. n Signiﬁcantly different when compared to the control group (Po0.05);
followed by Tukey’s test.
Fig. 3. Effects of carvacrol on TNF-a (A and B), IL-1b (C and D), and IL-10 (E and F) paw levels. Mice were injected with carvacrol (CA; 25–100 mg/kg), vehicle (5% Tween 20
plus saline; control group) or dexamethasone (Dexa; 2 mg/kg; reference drug) by the intraperitoneal route 40 min before the intraplantar injection of complete Freund’s
adjuvant (CFA). The saline group received intraplantar injection of saline (10 ml/paw) instead of CFA. The paw levels of TNF-a, IL-1b, and IL-10 were measured by ELISA 2 h
(A, C and E) or 2, 4, and 24 h (B, D and F) after the CFA injection. Data are reported as means7S.E.M.; n¼6 mice per group. n Signiﬁcantly different when compared to the
control group (Po0.01); # signiﬁcantly different from the saline group (Po0.01). One-way ANOVA followed by Tukey’s test.
Fig. 4. Effect of carvacrol on PGE2 paw levels. Mice were injected with carvacrol
(CA; 50 and 100 mg/kg), vehicle (5% Tween 20 plus saline; control group) or
dexamethasone (2 mg/kg; reference drug) by the intraperitoneal route 40 min
before the intraplantar injection of complete Freund’s adjuvant (CFA). The saline
group received intraplantar injection of saline (10 ml/paw) instead of CFA. The paw
levels PGE2 were measured by EIA 2 h after the CFA injection. Data are reported as
means7S.E.M.; n¼6 mice per group. n Signiﬁcantly different when compared to
the control group (Po0.05); #signiﬁcantly different when compared to the saline
group (Po0.01). One-way ANOVA followed by Tukey’s test.
Fig. 5. Effects of carvacrol on complete Freund’s adjuvant (CFA)-induced paw
inﬂammation in wild-type (WT) and IL-10-deﬁcient (IL-10 KO) mice. Paw edema
measured at 2, 4, 24, and 48 h after the CFA injection. Mice were injected with
carvacrol (100 mg/kg) or vehicle (5% Tween 20 in saline; control group) by the
intraperitoneal route 40 min before CFA (injected at time zero). Data are expressed
as means7S.E.M.; n¼6 mice per group. n Signiﬁcantly different when compared to
the WT/Vehicle group (Po0.01). Two-way ANOVA followed by Bonferroni’s test.
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demonstrated by in vitro and in vivo assays (Botelho et al., 2009;
Hotta et al., 2010; Landa et al., 2009; Wagner et al., 1986).
M.d.S. Lima et al. / European Journal of Pharmacology 699 (2013) 112–117116CFA, which consists of heat-killed mycobacteria suspended in
a mineral oil vehicle, produces a chronic inﬂammatory condition
when injected into rodents. It is well recognized that the injection
of CFA produces inﬂammation initiated by a local release of
mediators, such as cytokines and prostanoids, which are involved
in the inﬂammatory signs (Conti et al., 2004; Cunha and Ferreira,
2003; Dinarelo, 2000; Fehrenbacher et al., 2012; Woolf et al.,
1997). Therefore, to investigate the mechanisms involved in the
anti-inﬂammatory action of carvacrol, its possible modulatory
action on cytokine production was evaluated. Data obtained by
qRT-PCR and ELISA analyses show that carvacrol reduced the local
production of IL-1b, but not TNF-a, during paw inﬂammation. In
contrast, a recent work, Guimar~aes et al. (2012) demonstrated
that carvacrol decreased TNF-a concentrations in pleural lavage
ﬂuid in a mouse pleurisy model induced by carrageenan. The
difference on the effects in TNF-a production by carvacrol may
depend on the characteristics of the inﬂammation models (pleurisy
vs. paw inﬂammation) or on the inﬂammatory stimuli (carrageenan
vs. CFA) used in these studies. In fact, the cytokine response to
inﬂammation is extremely complex and depends on the inﬂamma-
tory stimuli (Fehrenbacher et al., 2012).
Cytokines are small regulatory proteins produced by white
blood cells and a variety of other cell types. Currently, it is well
accepted that cytokines constitute a link between cellular injuries
and signs of inﬂammation (Dinarello, 2000; Faccioli et al., 1990;
Verri et al., 2006). IL-1b is a pro-inﬂammatory cytokine that
induce the production of other inﬂammatory mediators involved
with cellular recruitment, fever, acute phase protein release,
increase of vascular permeability, and hyperalgesia (Dinarello,
1998). Considering the important role of IL-1b during the inﬂam-
matory response, it may be suggested that the anti-inﬂammatory
effects of carvacrol are related to an ability to inhibit the release
of this cytokine. It is known that IL-1b release precedes the
production of the ﬁnal inﬂammatory mediators, such as prosta-
glandins (Cunha et al., 2005; Verri et al., 2006). IL-1b stimulates
the expression of COX-2 and the subsequent production of
prostaglandins (Crofford et al., 1994; Zucali et al., 1986). Based
on the relevant anti-inﬂammatory action of non-steroidal anti-
inﬂammatory drugs and its cyclooxygenase inhibitory effect, it is
accepted that prostaglandins are important contributors of
inﬂammatory response. Since the inhibition of IL-1b release
might lead to the inhibition of prostanoid production, it is
possible that carvacrol acts by preventing the production of ﬁnal
mediators of inﬂammation. Aiming to evaluate this hypothesis,
the effect of carvacrol on PGE2 levels and COX-2 expression
were evaluated. In the present study, carvacrol decreased the
COX-2 mRNA expression and the PGE2 levels in the paw after the
CFA stimuli. Since the COX-2/PGE2 pathway is a key event
during different inﬂammatory conditions, the reduction of PGE2
levels and COX-2 expression can be responsible to the anti-
inﬂammatory effects of carvacrol.
To limit the deleterious consequences of prolonged inﬂamma-
tory reaction, the release of pro-inﬂammatory cytokines is
followed by the release of anti-inﬂammatory cytokines, such as
IL-4, IL-10, and IL-13, which inhibit the production and action of
the pro-inﬂammatory cytokines (Verri et al., 2006). IL-10, in fact,
acts as a potent anti-inﬂammatory cytokine by suppressing the
activation and function of immune cells. Accordingly, a crucial
effect of IL-10 is its ability to selectively block the expression of
pro-inﬂammatory cytokines (Moore et al., 2001), including IL-1b
(De Waal Malefyt et al., 1991; Karam et al., 2007). Thus, we
investigated the possibility that IL-10 production contributes to
the anti-inﬂammatory effect of carvacrol. Pretreatment with
carvacrol enhanced the local production of IL-10. Importantly,
the edema inhibition, reduction of PGE2 levels, and enhance of
IL-10 production were signiﬁcant at similar doses of carvacrol,showing that the anti-inﬂammatory effect parallels to the IL-10
release. It has been demonstrated that the inhibitory effects
of IL-10 on IL-1b and TNF-a production are crucial to its anti-
inﬂammatory activities, because these cytokines often have
synergistic activities on inﬂammatory processes, and amplify
these responses by inducing secondary mediators, such as che-
mokines and prostaglandins (Moore et al., 2001). In accordance,
IL-10 inhibits the production of PGE2, through down regulation of
COX-2 expression (Niiro et al., 1994, 1995). The present data
indicates that carvacrol, by stimulating the IL-10 action, produced
anti-edematogenic effects, down regulated the COX-2 expression,
and reduced the local levels of IL-1b and PGE2. The contribution of
IL-10 to the anti-inﬂammatory effect of carvacrol was conﬁrmed
in IL-10-deﬁcient mice, in which carvacrol did not produce anti-
edematogenic effect.5. Conclusions
In conclusion, it is possible to propose that the anti-inﬂammatory
properties of carvacrol are dependent on its ability to reduce the
production of inﬂammatory mediators, such as IL-1b and prosta-
noids, possibly through the induction of IL-10 release.Acknowledgment
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